Business Wire

CA-BEHAVIOSEC

21.4.2021 09:02:13 CEST | Business Wire | Press release

Share
Biometrics Experts and New Study Highlight How Behavioral Biometrics Supports Strict Regulation and Offers Better Data Privacy Protections

BehavioSec , the industry pioneer and technology leader for behavioral biometrics and continuous authentication, today announced new findings that organizations and consumers can feel more comfortable with wider use of behavioral biometrics to safeguard their online digital experiences and identities.

Following a year of digital transformation on a societal level, the demand for better online user experience and a stronger level of digital identity protection has become essential. With a year when the world has seen a combination of personal data theft with new rulings and proposed legislation, like the EU Schrems II in July 2020 and the US National Biometrics Information Privacy Act in August [US Senators Merkley, D-OR and Sanders, I-VT], the need for expert guidance has never been higher. BehavioSec shares this research and a company milestone to highlight how behavioral biometrics can be adopted transparently with clear benefits, and in compliant fashion with comprehensive data protection laws. These include measures like the European General Data Protection Regulation (GDPR), the European Commission’s PSD2/SCA and its Open Banking mandate, the US California Consumer Privacy Act (CCPA) and similar, anticipated requirements of regulations proposed in other regions.

To validate the safe use of behavioral biometrics at a time when headlines are full of allegations about technologies like facial recognition and “deep fake” simulations being abused, BehavioSec sponsored the report, “2021 Global Data Privacy Regulation of Physical & Behavioral Biometrics” by respected industry research firm Goode Intelligence . In the report, Chief Analyst Alan Goode dives into the relevance of current and proposed global privacy and data protection legislation on the successful and compliant adoption of biometrics technology for authentication and identity verification, and addresses the key questions organizations and consumers are asking:

  • Where do the next wave of behavioral-based technologies fit?
  • How do they impact our delicate balance between security, privacy, and regulation?
  • Are they covered under existing and proposed regulation?
  • Will behavior-based technology make matters worse - or much better?

Leveraging global bank customer input, extensive research, and legal opinion from attorneys at international law firm Osborne Clarke , the paper outlines how enterprises can confidently use behavioral biometrics while complying with some of the strictest privacy and data protection laws in the world, including GDPR, industry payment regulations like PSD2 SCA, and 3D Secure 2.0 technology.

“As we move more of our personal and business tasks online, it is becoming increasingly important to secure digital channels,” says Goode. “Mobile security is more important than ever before and behavioral biometric technology has proven itself as a vital tool in enabling secure access to digital services, preventing fraudsters from gaining access, all while remaining compliant to GDPR, among others.”

A US-based webcast, “Biometrics & Digital Identity Verification – 2021 Data Protection & Privacy Regulation Insights” will be broadcast on May 25, 2021 featuring a presentation by Alan Goode on his report’s findings and offer further insight on data privacy, digital transformation and fighting fraud and cybercrime using biometrics. Viewers can register to watch the webinar hosted by BehavioSec and IDG including a discussion between CSO’s Bob Bragdon, Alan Goode and an expert panel including Dr. Shane Shook, Financial Crimes Investigator and Venture Consultant at ForgePoint Capital, Jordan Blake, BehavioSec Vice President of Products, and Jake Bernstein J.D., attorney at Focal PLLC and former Washington State Assistant Attorney General.

“It is crucial to proactively stir these debates now on how new technologies define identity and authentication, before assumptions and lack of transparency – even if unintended – irrevocably shake public and policymakers’ trust,” added Jake Bernstein, who specialized in prosecuting consumer protection cases during his time in the U.S. Washington State Attorney General’s office. “The boundary between improving digital trust and triggering privacy and identity crises does not have to be a slippery slope where biometric-based systems are concerned. Yet, perceived missteps and alleged abuse of facial-recognition and other innovations to-date show us what stakeholders, including businesses, have to avoid.”

Additionally, on May 26th at 3:00pm BST/4:00pm CEST, Goode will host a second webcast, “2021 Global Regulation of Physical & Behavioral Biometrics for Digital Identity Verification” , to present his research on the impacts of privacy and data protection regulation on the implementation of biometrics by businesses, particularly across the European Union. As the Founder, CEO, and Chief Analyst of Goode Intelligence, Goode is a respected expert in information security and biometrics and will offer insights on how businesses may be able to consider their specific use cases and possible exceptions for explicit consent according to GDPR regulation. Goode will be joined by BehavioSec and international law firm Osborne Clarke, who BehavioSec commissioned to advise on the regulatory impact to customer deployments of the BehavioSec behavioral biometrics platform , specifically within the German banking sector.

“There’s no question that technology vendors need to continue to work collaboratively with government and business to ensure better protection and experience for consumers and employees while staying fully compliant,” said BehavioSec CEO Neil Costigan. “As the pioneer in this space, we’re offering this research to the market to open the dialogue, and we’re also demonstrating and modeling compliance as a company. Beyond our ongoing support of GDPR and security best practices, we are happy to share our recent SOC2 Type1 certification and our active program for Type 2 and ISO 27001.”

To access this research, the public can download Alan Goode’s report and join the public webcasts with CSO [IDG] in the US on May 25th and with Goode Intelligence in Europe on May 26th .

About BehavioSec

BehavioSec is the industry pioneer and technology leader for behavioral biometrics and continuous authentication, safeguarding millions of users and billions of transactions today.

Deployed across Global 2000 companies to dramatically reduce fraud, friction, threat, and theft, BehavioSec verifies and protects human digital identities by understanding how we uniquely type and swipe across our ever-changing devices. Whether used in the Cloud or on-premises, BehavioSec delivers the superior user experience, precision, and scale needed by organizations to keep customers engaged while catching evasive, real-time attacks other solutions miss.

Founded in the Nordics in 2008 out of groundbreaking research, industry-recognized BehavioSec partners with market leaders and organizations like DARPA, and has earned investment from top investment firms like ForgePoint Capital, Cisco, ABN AMRO, Conor Ventures, and Octopus Ventures. Headquartered in San Francisco, CA with offices worldwide, BehavioSec is ready to help you reduce risk, improve compliance, and digitally transform your distributed workforce and customer experience. www.behaviosec.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye